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Abstract
Background: Protein ubiquitination and/or degradation by the ubiquitin/proteasome system (UPS) have been recognized
as critical mechanisms in the regulation of numerous essential cellular functions. The importance of the UPS in viral
pathogenesis has become increasingly apparent. Using murine cardiomyocytes, we have previously demonstrated that the
UPS plays a key role in the replication of coxsackievirus B3 (CVB3), an important human pathogen associated with various
diseases. To further elucidate the underlying mechanisms, we examined the interplay between the UPS and CVB3, focusing
on the role of ubiquitination in viral lifecycle.
Methodology/Principal Findings: As assessed by in situ hybridization, Western blot, and plaque assay, we showed that
proteasome inhibition decreased CVB3 RNA replication, protein synthesis, and viral titers in HeLa cells. There were no
apparent changes in 20S proteasome activities following CVB3 infection. However, we found viral infection led to an
accumulation of protein-ubiquitin conjugates, accompanied by a decreased protein expression of free ubiquitin, implicating
an important role of ubiquitination in the UPS-mediated viral replication. Using small-interfering RNA, we demonstrated that
gene-silencing of ubiquitin significantly reduced viral titers, possibly through downregulation of protein ubiquitination and
subsequent alteration of protein function and/or degradation. Inhibition of deubiquitinating enzymes apparently enhances
the inhibitory effects of proteasome inhibitors on CVB3 replication. Finally, by immunoprecipitation, we showed that
coxsackieviral polymerase 3D was post-translationally modified by ubiquitination and such modification might be a
prerequisite for its function in transcriptional regulation of viral genome.
Conclusion: Coxsackievirus infection promotes protein ubiquitination, contributing to effective viral replication, probably
through ubiquitin modification of viral polymerase.
Citation: Si X, Gao G, Wong J, Wang Y, Zhang J, et al. (2008) Ubiquitination Is Required for Effective Replication of Coxsackievirus B3. PLoS ONE 3(7): e2585.
doi:10.1371/journal.pone.0002585
Editor: Dong-Yan Jin, University of Hong Kong, China
Received April 14, 2008; Accepted June 3, 2008; Published July 9, 2008
Copyright:  2008 Si et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Heart and Stroke Foundation of Canada (HSFC) (to
HL). XS is a recipient of the CIHR/HSFC IMPACT Post-Doctoral Fellowship, CIHR Michael Smith Fellowship and the HSFC Research Fellowship. GG is a recipient of a
Doctoral Traineeship from the HSFC and the MSFHR. HL is a New Investigator of the CIHR/St. Paul’s Hospital Foundation Award and a Scholar of the Michael Smith
Foundation for Health Research (MSFHR).
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hluo@mrl.ubc.ca
Introduction
Coxsackievirus B3 (CVB3), a small RNA virus in the
picornaviridae family, is an important human pathogen associated
with various diseases, including myocarditis, aseptic meningitis,
pancreatitis and possibly insulin-dependent diabetes. We and
others have shown that CVB3 infection leads to activation of
several intracellular signaling pathways [1–7], and downregulation
of host proteins likely through the ubiquitin/proteasome system
(UPS) [7–9].
It is well-established that the UPS is the major intracellular
proteolytic system of all eukaryotic cells [10,11]. The ATP-
dependent system begins with covalent attachment of ubiquitin to
the ubiquitin-activating enzyme (E1). Then the ubiquitin is
transferred to a ubiquitin-conjugating enzyme (E2). Finally,
ubiquitin ligase (E3) transfers the ubiquitin to the substrate
protein. After several cycles of ubiquitination, multiple ubiquitin
molecules are attached to the substrate which is then quickly
recognized and subsequently degraded by the 26S proteasome.
Ubiquitin is recycled through the actions of deubiquitinating
enzymes (DUBs) [12,13]. There are at least two classes of
deubiquitinating enzymes, the ubiquitin C-terminal hydrolases
(UCHs) and ubiquitin-specific processing proteases family.
In addition to the degradation of mutant, damaged and
misfolded proteins, this system is responsible for the modulation
of many regulatory proteins such as cyclins [14], inhibitors of
cyclin-dependent kinases (p21, p27) [15], tumor suppressors (p53)
[16], and inhibitor of NFkB( I kB) [17], which are essential for a
variety of cellular functions, including cell-cycle regulation,
apoptosis and host immune responses [18]. Unlike polyubiquitina-
tion in the regulation of protein degradation, monoubiquitination
of cellular proteins, such as histones, calmodulins, actin,
proliferating cell nuclear antigen and receptor tyrosine kinases,
plays more diversified roles involving in the regulation of
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endocytosis [19].
Since the first discovery that human papillomavirus protein E6
targets the cellular tumor suppressor protein p53 for the UPS-
mediated degradation [16], increasing studies, including those
from our laboratory, have suggested that various viruses evolve
different mechanisms to utilize or manipulate the host UPS for
their own benefits [9,20–25]. We have previously shown that
CVB3 infection results in downregulation of several host proteins
[7,9], such as cell-cycle protein cyclin D1, tumor suppressor p53,
and transcription activator b-catenin in infected HeLa cells. The
downregulation of host proteins following CVB3 infection is most
likely through the UPS. Specific inhibitors to 26S proteasome
reverse the degradation of proteins in HeLa cells [7,9] and reduce
CVB3 replication in murine cardiomyocytes [26].
In this study, we investigated the possible underlying mechanisms
by which the UPS regulates CVB3 replication. We demonstrated
that protein ubiquitination was enhanced after coxsackievirus
infection. We further showed that knockdown of ubiquitin
expression by small-interfering RNA (siRNA) decreased CVB3
infection, likely through the downregulation of ubiquitination and
subsequent alteration of protein function and/or degradation. In
addition, we showed that inhibition of deubiquitinating enzyme
increased the inhibitory effects of proteasome inhibitors on CVB3
replication. We also found that CVB3 RNA-dependent RNA
polymerase 3D (3D
pol) was modified by ubiquitination. Taken
together, our study suggests an important role of ubiquitination in
the regulation of coxsackieviral replication.
Results
Proteasome inhibition reduces CVB3 infection in HeLa
cells
To uncover the underlying mechanisms of the antiviral activities
of proteasome inhibitors, we chose to use the well-characterized
HeLa cells to further our study. We first examined the role of
proteasome inhibition in CVB3 replication. As shown in Fig. 1, we
found that proteasome inhibitor, MG132, significantly reduced
CVB3 viral RNA synthesis (Fig. 1A). Both proteasome inhibitors
used in the study, MG132 and lactacystin, decreased the synthesis
of CVB3 capsid protein, VP1, in a dose-dependent manner
(Fig. 1B). In addition, two inhibitors inhibited CVB3 viral titers by
up to fifteen folds (Fig. 1C). Although MG132 and lactacystin
significantly inhibited cellular 20S proteasome activities, we have
previously demonstrated there was no apparent difference in
proteasome activities between CVB3-infected and sham-infected
HeLa cells [9]. Together, these results suggest that efficient
replication of CVB3 requires the intact UPS function rather than
the core proteasome activity alone.
We also performed cell viability assay and morphological
examination to determine whether inhibiting viral replication by
proteasome inhibitors is due to the toxicity. We found that there
was no measurable cell death throughout the incubation period for
all doses of proteasome inhibitors used in this study (Fig. 1D). On
the contrary, virus-induced cell death was markedly inhibited after
the treatment of proteasome inhibitors as a result of decreased
viral replication (Fig. 1D).
CVB3 infection promotes protein ubiquitination
As alluded to earlier, two successive steps are involved in protein
degradation: (1) covalent attachment of ubiquitins to the target
protein substrate, and (2) degradation of the polyubiquitinated
protein by the 26S proteasome with the release of ubiquitin for
recycling. To dissect out the role of ubiquitination and
degradation in CVB3 infection, we next decided to investigate
the protein ubiquitination after CVB3 infection. As shown in
Fig. 2A, protein ubiquitination was gradually increased along the
time-course of CVB3 infection, which was accompanied by a
decrease of free ubiquitin levels. Densitometric analysis further
demonstrated that the increases in protein ubiquitination at 3 h,
5 h, and 7 h post-infection were statistically significant as
compared to sham infection (Fig. 2B). We have previously
demonstrated that 26S proteasome activities were unchanged
during CVB3 infection [9]. Thus, the finding of increased
accumulation of ubiquitinated proteins is likely due to enhanced
protein ubiquitination as opposed to reduced proteasome activity.
Decreased levels of free ubiquitin could be a direct consequence of
the increased protein ubiquitination. These results suggest that
enhanced ubiquitin conjugation may be a prerequisite for efficient
synthesis of CVB3 viral RNA and continuation of its lifecycle.
Knockdown of ubiquitin by siRNA reduces CVB3 infection
In addition to blocking proteasome proteolytic activities,
proteasome inhibitors are known to reduce free ubiquitin levels
in treated cells [27]. It has been suggested that proteasome
inhibition negatively affects the budding of retroviruses through
reducing free ubiquitin level and subsequently interfering with
ubiquitination of viral Gag proteins [22,24,25]. Ubiquitin is
generated in the cell by proteolysis of polyubiquitinated proteins or
ubiquitin fused to carboxyl extension proteins (CEPs) [28]. To
investigate whether protein ubiquitination is beneficial to CVB3
replication in HeLa cells, we used the ubiquitin-specific siRNA to
gene-silence the expression of human ubiquitin-CEP Uba80,
which codes for ubiquitin fused to ribosomal protein S27a [29]. As
shown in Fig. 3A, both ubiquitin conjugates and free ubiquitin
levels were markedly knocked down after the treatment of
ubiquitin siRNA. We further showed that viral titers were
significantly reduced in the ubiquitin siRNA-transfected cells as
compared to scramble siRNA control (Fig. 3B), suggesting that
protein ubiquitination is a critical process adopted by coxsackie-
virus for the successful completion of its lifecycle.
DUB inhibition further enhances the inhibitory effects of
proteasome inhibitor on CVB3 replication
It has been demonstrated that protein ubiquitination can also be
regulated by deubiquitinating enzymes that specifically cleave
ubiquitin from ubiquitin-conjugated protein substrates [12,13,30].
To further explore the role of protein ubiquitination in viral
replication, we examined the influence of DUB inhibition on viral
protein expression. Two commercially available ubiquitin c-
terminal hydrolase inhibitors, UCH L1 and UCH L3 inhibitors,
were used for this study. As shown in Fig. 4, specific inhibition of
UCH L1 or UCH L3 further reduced CVB3 protein expression
and virus titers in proteasome inhibitor-treated cells, suggesting
that these enzymes may be involved in the lifecycle of CVB3.
Nevertheless, it was found that inhibition of the UCH L1 and L3
activities alone was not sufficient to block coxsackievirus
replication since no significant changes in viral protein expression
and CVB3 titers were observed in cells treated with two UCH
inhibitors either separately or in combination (Fig. 4). As discussed
earlier, stabilization of short-lived host proteins and prevention of
protein ubiquitination by reducing recycled ubiquitin likely
contribute to the inhibitory effect of proteasome inhibition on
viral replication. Thus, it is speculated that DUB inhibition by
UCHL1/L3 inhibitors alone, in the absence of apparent inhibition
of protein degradation, is not sufficient enough to block viral
replication. However, additional reduction of recycled free
CVB3 and Ubiquitination
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effect of proteasome inhibitor.
CVB3 RNA-dependent RNA polymerase 3D is
ubiquitinated
Some virus RNA-dependent RNA polymerases including the
sindbis virus and the turnip yellow mosaic virus RNA polymerases
have been demonstrated to be phosphorylated and ubiquitinated
[31]. Although the role of ubiquitination of these RNA
polymerases in the regulation of virus replication remains to be
determined, such observation raises the interesting possibility that
the ubiquitin/proteasome system may regulate CVB3 replication
through ubiquitinating viral polymerase 3D, which is essential for
initiating viral RNA replication. To examine whether coxsack-
ieviral proteins are subjected to ubiquitination during viral
infection, we performed immunoprecipitation with anti-ubiquitin
antibody, followed by immunoblots using antibodies against 3D
pol
and viral capsid protein VP1, respectively. As shown in Fig. 5,
immunoreactive bands of around 60 kDa were detected in CVB3-
infected cells. Non-modified 3D
pol has a molecular weight of about
53 kDa, thus this observation suggests that 3D
pol likely undergoes
post-translational modification by monoubiquitination. No protein
ubiquitination was observed for VP1 (data not shown). Our results
Figure 1. Proteasome inhibitors decrease coxsackieviral RNA expression, viral protein synthesis and viral progeny release in HeLa
cells. HeLa cells were sham-infected with PBS or infected with CVB3 in the presence or absence of MG132 or lactacystin. (A). Seven hours post-
infection (pi), positive-stranded viral RNA was determined by in situ hybridization using anti-sense riboprobes for CVB3 (red). Cell nuclei were
counterstained with hematoxylin (blue). (B). Cell lysates were collected at 7 h pi and immunoblotted with anti-VP1 and anti-b-actin (loading control)
antibodies. (C). Medium was collected from CVB3-infected cells at 16 h pi and virus titer was determined by plaque assays. The data shown are
mean6SE (standard errors) from three independent experiments.
# p,0.001 as compared to CVB3 infection without treatment. (D). Cell viability
assay was performed at 16 h pi by the MTS assay which measures mitochondrial function (mean6SE, n=3). One hundred percent survival was
defined as the level of MTS in sham-infected cells in the absence of MG132.
# p,0.001 as compared to CVB3 infection only without MG132
treatment.
doi:10.1371/journal.pone.0002585.g001
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might be required for successful replication of the virus.
Effects of CVB3 infection on protein expression of several
key enzymes involved in the process of ubiquitination
and deubiquitination
In trying to understand the mechanisms by which CVB3
manipulates the UPS, we examined the protein expression of
several key enzymes involved in the process of protein ubiquitina-
tion and deubiquitination. We measured expression levels of
ubiquitin-activating enzyme E1A/E1B, ubiquitin-conjugating
enzyme Ubc H7, ubiquitin C-terminal hydrolase and two p53-
related E3 ligases, human papillomavirus E6-associated protein
and mouse double minute 2 homolog. However, no apparent
changes were observed during the time-course of CVB3 infection
(data not shown). These results indicate that the manipulation of
the UPS by CVB3 is unlikely regulated by the above-examined
ubiquitin-related key enzymes or molecules. Future studies will
determine whether CVB3 infection targets on specific ubiquitin
ligases or deubiquitinating enzymes.
Discussion
In the present study, we have provided further evidence that
CVB3 manipulates the UPS for its infection. CVB3 infection results
in increased protein polyubiquitination and a subsequent decrease
in free ubiquitin levels. Knockdown of ubiquitin and ubiquitin-
mediated protein modification and/or degradation by siRNA
Figure 2. CVB3 infection results in increased protein poly-
ubiquitination and decreased free ubiquitin. (A). HeLa cells were
infected with CVB3 or sham-infected with PBS. At different timepoints
after viral infection, cell lysates were collected and immunoblotted with
anti-ubiquitin, anti-VP1 and anti-b-actin (loading control) antibodies as
described in ‘‘Material and Methods’’. Protein levels of protein-ubiquitin
conjugates (molecular weight starting from 82.2 kDa to approximately
230 kDa) and free ubiquitin were quantitated by densitometric analysis
using NIH ImageJ program and normalized to the sham infection, which
was arbitrarily set to a value of 1.0. Similar results were observed in two
independent experiments. (B). Statistical analysis of protein-ubiquitin
conjugates at 3 h, 5 h and 7 h after CVB3 infection. The data represent
mean6SE of five different experiments. * p,0.05;
& p,0.01 as
compared to protein expression in sham infection.
doi:10.1371/journal.pone.0002585.g002
Figure 3. Knockdown of ubiquitin expression by siRNA reduces
CVB3 replication. HeLa cells were transiently transfected with the
ubiquitin siRNA or a scramble control siRNA. Twenty-four hours post-
transfection, HeLa cells were infected with CVB3 or sham-infected with
PBS. Cell lysates were collected at the indicated timepoints. (A).
Immunoblot was performed with anti-ubiquitin and anti-b-actin
(loading control) antibodies. (B). Supernatants of infected cells were
collected at 7 h pi to measure CVB3 progeny virion release by plaque
assay (Mean6SE, n=4). Results represent data from three independent
experiments. * p,0.05 as compared to virus titers in scramble siRNA-
transfected cells.
doi:10.1371/journal.pone.0002585.g003
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supporting the essential roles of the UPS in the replication of CVB3.
It is increasingly apparent that viruses can evolve various
strategies to utilize the host UPS for their own benefits. The UPS
has been suggested to play a critical role in the different steps of
viral lifecycle, including viral entry, viral replication, maturation,
viral progeny release, and latent virus reactivation [32–34]. The
mechanisms that the UPS regulates viral infection involve
degrading intracellular proteins or excessive viral proteins that
are against efficient viral replication and modulating viral protein
function through ubiquitin-mediated modification or by directly
encoding ubiquitin-related enzymes [35].
Figure 4. DUB inhibition further enhances the inhibitory effect of proteasome inhibitors on CVB3 replication. HeLa cells were infected
with CVB3 or sham-infected with PBS, UCH L1 inhibitor, UCH L3 inhibitor and proteasome inhibitor MG132 were added 1 h pi as indicated. Seven
hours pi, cell lysates and supernatant were collected for immunoblotting and plaque assay, respectively. (A). Immunoblot was performed using anti-
VP1 and anti-b-actin (loading control) antibodies. Similar results were observed in two independent experiments. (B). Virus titer was measured by
plaque assay (Mean6SE, n=4). Results represent data from three independent experiments.
# p,0.001 as compared to CVB3 infection only without
treatment;
& p,0.01 as compared to MG132 treatment alone.
doi:10.1371/journal.pone.0002585.g004
CVB3 and Ubiquitination
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ubiquitination without inhibition of the core 20S proteasome
activity highlights the possibility that CVB3 manipulates the UPS
to destabilize or modulate the host and viral proteins. Poly-
ubiquitination and degradation of host antiviral proteins has been
suggested to be a mechanism of HIV-1 replication [36] . We have
previously identified several proteins, such as cyclin D1, p53 and
b-catenin, which are downregulated through the UPS after CVB3
infection [7,9]. Destabilization of these short-lived host proteins is
likely required for CVB3 viral RNA and protein synthesis in its
lifecycle. Moreover, it is speculated that nonstructural viral
proteins of CVB3 could also be potential targets of the UPS for
degradation. Previous studies on picornavirus have shown that
several viral proteins, such as encephalomyocarditis virus (EMCV)
3C protease and hepatitis A virus (HAV) 3C protease, are
ubiquitinated and present in low concentrations in infected cells
[37–39]. Several E3 ubiquitin ligases, such as human E3a
ubiquitin ligase, have been shown to catalyze the ubiquitination
of these viral proteins [38,39]. Although the exact role of
ubiquitination and subsequent degradation of nonstructural viral
proteins of EMCV and HAV in infected cells remains elusive, such
rapid turnover may be required for efficient viral RNA replication,
viral protein synthesis and virus maturation.
As alluded to earlier, DUBs are a large family of cysteine
protease responsible for the removal of ubiquitin from substrate
proteins [40]. It is estimated that the human genome encodes
more than 100 DUBs. Although UCHL1 is identified as an
important DUB, inhibition of UCHL1 alone has been shown to
only partially block the activities of DUBs [41]. Thus, the finding
in this study that UCHL1/L3 inhibition is not as efficient in
blocking viral replication as general inhibition of proteasome
function or knockdown of ubiquitin is likely attributed to
incomplete inhibition of DUBs by UCHL1/L3 inhibitors.
In addition to protein degradation, ubiquitin-modification has
been suggested to be involved in the regulation of protein function.
It was reported that monoubiquitination of the Gag protein of
retroviruses is required for virus budding [22,24,25]. Depletion of
free ubiquitin by proteasome inhibitors prevents Gag ubiquitina-
tion, subsequently blocks virus progeny release/budding. In
addition, ubiquitination of human immunodeficiency virus type
1 Tat protein and human T-cell leukemia virus type 1 Tax protein
has been shown to modulate their transactivation activities
[20,23]. We speculate that monoubiquitination is also an
important machinery for post-translational modification and
activation of CVB3 viral proteins. In the current study, we have
shown that CVB3 RNA-dependent RNA polymerase 3D is post-
translationally modified by ubiquitination, suggesting a critical role
of protein ubiquitination in the regulation of viral protein
functions.
Based on the results in the manuscript, in combination of our
previous findings that CVB3 infection promotes host protein
degradation, including cyclin D1, p53 and b-catenin, a model
system on the role of the UPS in CVB3 replication is proposed in
Fig. 6. Coxsackievirus infection facilitates host protein polyubi-
quitination, which subsequently increases intracellular protein
degradation by the proteasome and/or viral protein modification,
such as 3D
pol, by monoubiquitination. Degradation of host
antiviral proteins provides a favorable environment for virus to
achieve successful replication. Knockdown of ubiquitin decreases
host protein degradation and viral protein ubiquitination. Protea-
some inhibition blocks host protein degradation and viral protein
ubiquitination by reducing recycled ubiquitin. DUB inhibitors
further decreases the viral replication when used together with
proteasome inhibitors through the additional reduction of recycled
free ubiquitin.
In conclusion, we have demonstrated for the first time that
CVB3 infection results in increased protein ubiquitination and
consequent decreases in free ubiquitin levels. We further
demonstrate that protein ubiquitination is required for the
completion of viral lifecycle, likely through ubiquitin modification
of viral polymerase.
Materials and Methods
Cell culture, virus, and materials
HeLa cells (American Type Culture Collection) were grown and
maintained in complete medium [Dulbecco’s modified Eagle’s
media (DMEM) supplemented with 10% heat-inactivated new-
born calf serum (NCS) (Invitrogen)]. CVB3 (Kandolf strain) was
propagated in HeLa cells and stored at 280uC. Virus titer was
routinely determined by a plaque assay prior to infection as
described below.
The monoclonal anti-b-actin and anti-ubiquitin antibodies were
purchased from Sigma-Aldrich. The monoclonal anti-VP1
antibody was obtained from DakoCytomation. The ubiquitin
siRNA, scramble control siRNA, and horseradish peroxidase-
conjugated secondary antibodies were obtained from Santa Cruz
Biotechnology. The proteasome inhibitors, MG132 and lactacys-
tin, the UCH L1 inhibitor (LDN-57444) and the UCH L3
inhibitor (4,5,6,7-Tetrachloroindan-1,3-dione), and the polyclonal
anti-ubiquitin antibody were obtained from Calbiochem. The
polyclonal anti-3D
pol antibody was a generous gift from Dr. Karin
Klingel (University Hospital Tuebingen, Germany).
Virus infection
HeLa cells were grown in complete medium to 70–80%
confluence, and then infected at a multiplicity of infection (MOI)
of 10 with CVB3 or sham-infected with phosphate-buffered saline
(PBS) for 1 h in serum-free DMEM. Cells were then washed with
PBS and cultured in serum-free medium. For inhibition
experiments, HeLa cells were infected with CVB3 for 1 h, washed
with PBS, and then incubated with DMEM containing various
concentrations of inhibitors.
Figure 5. CVB3 RNA-dependent RNA polymerase 3D is
ubiquitinated. HeLa cells were infected with CVB3 or sham-infected
with PBS for 7 h, Cell lysates were collected and immuoprecipitated (IP)
with a monoclonal anti-ubiquitin antibody. Protein-ubiquitin conju-
gates were detected by immunoblots (IB) using a polyclonal anti-3D
pol
antibody. Immunoblot for antibody IgG was shown as loading controls.
Similar results were observed in three independent experiments.
doi:10.1371/journal.pone.0002585.g005
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Cell lysates were prepared using lysis buffer (50 mM pyrophos-
phate, 50 mM NaF, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA,
100 mMN a 3VO4, 10 mM HEPES (pH 7.4), 0.1% Triton X-100,
and the protease inhibitor cocktail) as described previously [2]. For
immunoblot analysis, equal amounts of protein were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and then transferred to nitrocellulose membranes (GE
Healthcare). Membranes were blocked for 1 h with nonfat dry
milk solution (5% in PBS) containing 0.1% Tween 20. Blots were
then incubated for 1 h with the primary antibody followed by
incubation for 1 h with the secondary antibody. Immunoreactive
bands were visualized by enhanced chemiluminescence (GE
Healthcare). When protein ubiquitination was examined, mem-
brane was heat-activated by autoclaving at 121uC for 35 min prior
to blocking with nonfat dry milk solution to enhance antigenic site
recognition.
For immunoprecipitation, cells were lysed using the above-
described lysis buffer with freshly added 20 mM iodoacetamide. A
total of 500 mg of cell lysates were incubated with a monoclonal
anti-ubiquitin antibody (1:100) at 4uC overnight, followed by 2 h
incubation with protein G-agorose beads (Amersham). Immuno-
complexes were washed five times with the lysis buffer containing
20 mM iodoacetamide, and then boiled for 5 min in the 26non-
reducing sample buffer which lacks both b-mercaptoethanol and
DTT, but with addition of 20 mM iodoacetamide. After
centrifugation, the precipitated proteins were separated by SDS-
PAGE. Ubiquitin conjugates were analyzed by immunoblot using
polyclonal anti-3D
pol antibody.
Viral RNA in situ hybridization
HeLa cells were grown and maintained on two-chamber culture
slides (Becton Dickinson Labware). Subconfluent cells were
infected with either PBS or CVB3 (MOI=10). Following 1 h of
incubation at 37uC, cells were washed with PBS and replenished
with complete medium in the absence and presence of MG132.
HeLa cells were incubated for an additional 6 h. The culture slides
were then washed gently with PBS, fixed with formalin buffer for
15 min, and then air-dried at room temperature. Culture slides
were then subjected to in situ hybridization assays to detect the
sense-strand of CVB3 genomic RNA as previously described [26].
Plaque assay
CVB3 titer in cell supernatant was determined on monolayers
of HeLa cells by an agar overlay plaque assay in triplicate as
described previously [2]. Briefly, samples were serially diluted and
overlaid on monolayer of HeLa cells. After 1 h incubation,
medium was replaced with complete medium containing 0.75%
agar. Cells were incubated for 72 h, then fixed with Carnoy’s
fixative (75% ethanol-25% acetic acid), and stained with 1%
crystal violet. Plaques were counted and viral titer was calculated
as plaque forming unit (PFU) per milliliter.
Cell Viability Assay
MTS (3, 4-(5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy phe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium salt, Promega) assay was
performed to determine cell viability as previously described [7].
Briefly, cells were incubated with MTS solution for 2 h prior to
collection. Absorbance was measured at a wave length of 490 nm
using an ELISA reader.
Ubiquitin siRNA transfection
HeLa cells were grown to 50% confluency and then transiently
transfected with ubiquitin-specific siRNA (200 nM) using oligo-
fectamine according to the manufacturer’s suggestion (Invitrogen).
A scramble siRNA (200 nM) was used as a control. The silencing
efficiency was detected by immunoblot analyses using the anti-
ubiquitin antibody. After 24 h of transfection, cells were infected
with CVB3 as indicated.
Statistical analysis
Statistical analysis was performed using the paired Student’s t test.
A p value of less than or equal to 0.05 was considered statistically
significant.
Figure 6. A proposed model for UPS regulation of CVB3 replication (See text). Abbreviation: CVB3, coxsackievirus B3; Ub, ubiquitin; DUBs,
deubiquitinating enzymes; siRNA, small-interfering RNA; 3D
pol, coxsackievirus RNA-dependent RNA polymerase 3D.
doi:10.1371/journal.pone.0002585.g006
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